FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136361932> ?p ?o ?g. }

• W3136361932 endingPage "80.e8" @default.
• W3136361932 startingPage "66" @default.
• W3136361932 abstract "Background & aimsIn celiac disease (CeD), gluten induces immune activation, leading to enteropathy. TAK-101, gluten protein (gliadin) encapsulated in negatively charged poly(dl-lactide-co-glycolic acid) nanoparticles, is designed to induce gluten-specific tolerance.MethodsTAK-101 was evaluated in phase 1 dose escalation safety and phase 2a double-blind, randomized, placebo-controlled studies. Primary endpoints included pharmacokinetics, safety, and tolerability of TAK-101 (phase 1) and change from baseline in circulating gliadin-specific interferon-γ–producing cells at day 6 of gluten challenge, in patients with CeD (phase 2a). Secondary endpoints in the phase 2a study included changes from baseline in enteropathy (villus height to crypt depth ratio [Vh:Cd]), and frequency of intestinal intraepithelial lymphocytes and peripheral gut-homing T cells.ResultsIn phase 2a, 33 randomized patients completed the 14-day gluten challenge. TAK-101 induced an 88% reduction in change from baseline in interferon-γ spot-forming units vs placebo (2.01 vs 17.58, P = .006). Vh:Cd deteriorated in the placebo group (−0.63, P = .002), but not in the TAK-101 group (−0.18, P = .110), although the intergroup change from baseline was not significant (P = .08). Intraepithelial lymphocyte numbers remained equal. TAK-101 reduced changes in circulating α4β7+CD4+ (0.26 vs 1.05, P = .032), αEβ7+CD8+ (0.69 vs 3.64, P = .003), and γδ (0.15 vs 1.59, P = .010) effector memory T cells. TAK-101 (up to 8 mg/kg) induced no clinically meaningful changes in vital signs or routine clinical laboratory evaluations. No serious adverse events occurred.ConclusionsTAK-101 was well tolerated and prevented gluten-induced immune activation in CeD. The findings from the present clinical trial suggest that antigen-specific tolerance was induced and represent a novel approach translatable to other immune-mediated diseases.ClinicalTrials.gov identifiers: NCT03486990 and NCT03738475. In celiac disease (CeD), gluten induces immune activation, leading to enteropathy. TAK-101, gluten protein (gliadin) encapsulated in negatively charged poly(dl-lactide-co-glycolic acid) nanoparticles, is designed to induce gluten-specific tolerance. TAK-101 was evaluated in phase 1 dose escalation safety and phase 2a double-blind, randomized, placebo-controlled studies. Primary endpoints included pharmacokinetics, safety, and tolerability of TAK-101 (phase 1) and change from baseline in circulating gliadin-specific interferon-γ–producing cells at day 6 of gluten challenge, in patients with CeD (phase 2a). Secondary endpoints in the phase 2a study included changes from baseline in enteropathy (villus height to crypt depth ratio [Vh:Cd]), and frequency of intestinal intraepithelial lymphocytes and peripheral gut-homing T cells. In phase 2a, 33 randomized patients completed the 14-day gluten challenge. TAK-101 induced an 88% reduction in change from baseline in interferon-γ spot-forming units vs placebo (2.01 vs 17.58, P = .006). Vh:Cd deteriorated in the placebo group (−0.63, P = .002), but not in the TAK-101 group (−0.18, P = .110), although the intergroup change from baseline was not significant (P = .08). Intraepithelial lymphocyte numbers remained equal. TAK-101 reduced changes in circulating α4β7+CD4+ (0.26 vs 1.05, P = .032), αEβ7+CD8+ (0.69 vs 3.64, P = .003), and γδ (0.15 vs 1.59, P = .010) effector memory T cells. TAK-101 (up to 8 mg/kg) induced no clinically meaningful changes in vital signs or routine clinical laboratory evaluations. No serious adverse events occurred. TAK-101 was well tolerated and prevented gluten-induced immune activation in CeD. The findings from the present clinical trial suggest that antigen-specific tolerance was induced and represent a novel approach translatable to other immune-mediated diseases." @default.
• W3136361932 created "2021-03-29" @default.
• W3136361932 creator A5002209179 @default.
• W3136361932 creator A5002687023 @default.
• W3136361932 creator A5006238718 @default.
• W3136361932 creator A5016900766 @default.
• W3136361932 creator A5018264898 @default.
• W3136361932 creator A5021367289 @default.
• W3136361932 creator A5025820462 @default.
• W3136361932 creator A5026208455 @default.
• W3136361932 creator A5028389258 @default.
• W3136361932 creator A5028863296 @default.
• W3136361932 creator A5033876610 @default.
• W3136361932 creator A5036976413 @default.
• W3136361932 creator A5047129298 @default.
• W3136361932 creator A5047373886 @default.
• W3136361932 creator A5051179586 @default.
• W3136361932 creator A5066621036 @default.
• W3136361932 creator A5069162704 @default.
• W3136361932 creator A5069703075 @default.
• W3136361932 creator A5072090754 @default.
• W3136361932 creator A5072446366 @default.
• W3136361932 creator A5077468407 @default.
• W3136361932 creator A5085087229 @default.
• W3136361932 creator A5086456758 @default.
• W3136361932 creator A5088772826 @default.
• W3136361932 date "2021-07-01" @default.
• W3136361932 modified "2023-10-16" @default.
• W3136361932 title "TAK-101 Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease: A Randomized, Double-Blind, Placebo-Controlled Study" @default.
• W3136361932 cites W1507805073 @default.
• W3136361932 cites W1558288119 @default.
• W3136361932 cites W1607905633 @default.
• W3136361932 cites W1649418318 @default.
• W3136361932 cites W1811817270 @default.
• W3136361932 cites W1896583420 @default.
• W3136361932 cites W1968973890 @default.
• W3136361932 cites W1969309327 @default.
• W3136361932 cites W1978684572 @default.
• W3136361932 cites W1993322661 @default.
• W3136361932 cites W1994808474 @default.
• W3136361932 cites W2005459818 @default.
• W3136361932 cites W2018896468 @default.
• W3136361932 cites W2020626093 @default.
• W3136361932 cites W2026601103 @default.
• W3136361932 cites W2028797913 @default.
• W3136361932 cites W2038254572 @default.
• W3136361932 cites W2069642599 @default.
• W3136361932 cites W2086547450 @default.
• W3136361932 cites W2105838733 @default.
• W3136361932 cites W2111006781 @default.
• W3136361932 cites W2111452470 @default.
• W3136361932 cites W2119815939 @default.
• W3136361932 cites W2141637849 @default.
• W3136361932 cites W2146100358 @default.
• W3136361932 cites W2146868709 @default.
• W3136361932 cites W2156964052 @default.
• W3136361932 cites W2165428460 @default.
• W3136361932 cites W2324016220 @default.
• W3136361932 cites W2338589974 @default.
• W3136361932 cites W2527704261 @default.
• W3136361932 cites W2588975580 @default.
• W3136361932 cites W2602756509 @default.
• W3136361932 cites W2610643013 @default.
• W3136361932 cites W2614090121 @default.
• W3136361932 cites W2775438937 @default.
• W3136361932 cites W2792440444 @default.
• W3136361932 cites W2793797392 @default.
• W3136361932 cites W2916006516 @default.
• W3136361932 cites W2944987175 @default.
• W3136361932 cites W2968051761 @default.
• W3136361932 cites W3004735824 @default.
• W3136361932 cites W3095735207 @default.
• W3136361932 cites W4211144941 @default.
• W3136361932 cites W4236836788 @default.
• W3136361932 cites W4251897673 @default.
• W3136361932 cites W4292528167 @default.
• W3136361932 cites W81942398 @default.
• W3136361932 doi "https://doi.org/10.1053/j.gastro.2021.03.014" @default.
• W3136361932 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33722583" @default.
• W3136361932 hasPublicationYear "2021" @default.
• W3136361932 type Work @default.
• W3136361932 sameAs 3136361932 @default.
• W3136361932 citedByCount "72" @default.
• W3136361932 countsByYear W31363619322021 @default.
• W3136361932 countsByYear W31363619322022 @default.
• W3136361932 countsByYear W31363619322023 @default.
• W3136361932 crossrefType "journal-article" @default.
• W3136361932 hasAuthorship W3136361932A5002209179 @default.
• W3136361932 hasAuthorship W3136361932A5002687023 @default.
• W3136361932 hasAuthorship W3136361932A5006238718 @default.
• W3136361932 hasAuthorship W3136361932A5016900766 @default.
• W3136361932 hasAuthorship W3136361932A5018264898 @default.
• W3136361932 hasAuthorship W3136361932A5021367289 @default.
• W3136361932 hasAuthorship W3136361932A5025820462 @default.
• W3136361932 hasAuthorship W3136361932A5026208455 @default.
• W3136361932 hasAuthorship W3136361932A5028389258 @default.
• W3136361932 hasAuthorship W3136361932A5028863296 @default.
• W3136361932 hasAuthorship W3136361932A5033876610 @default.

• next